NAP (Naptumomab estafenatox)
NT-NAP-102-1
Phase 2 small_molecule completed
Quick answer
NAP (Naptumomab estafenatox) for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed